Protocol No.: COG-AALL1621

Title
AALL1621 - A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Principal Investigator
Paul, Stephan
Phase
II
Age Group
Both
Applicable Disease Site
Leukemia
Participating Institution
Mary Babb Randolph Cancer Center
Contacts
Jan Rapp
Clinical Trials Manager
Phone: +1 304-293-1229
Carla Corbin, RN, BSN
Nurse Clinician
Phone: +1 304-293-1217
April Shay, MSN, PNP-BC
Nurse Practitioner
Phone: +1 304-293-1217
Denise Casino
Clinical Trials Manager
Phone: +1 304-293-0735

View on ClinicalTrials.gov